-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HPN-328 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HPN-328 in Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HPN-328 in Pancreatic Cancer Drug Details: HPN-328 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HPN-328 in Bladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HPN-328 in Bladder Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HPN-328 in Bladder Cancer Drug Details: HPN-328 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HPN-328 in Thymic Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HPN-328 in Thymic Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HPN-328 in Thymic Carcinoma Drug Details: HPN-328 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HPN-328 in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HPN-328 in Small-Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HPN-328 in Small-Cell Lung Cancer Drug Details: HPN-328 is under development...
-
Product Insights
NewThymic Carcinoma – Drugs In Development, 2024
Empower your strategies with our Thymic Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Thymic carcinoma is a rare and aggressive cancer that originates from the epithelial cells of the thymus, a gland in the chest that produces immune cells. Thymic carcinoma often spreads to other organs and is resistant to chemotherapy. The symptoms may include chest pain, cough, difficulty breathing, and weight loss. The diagnosis is based on imaging tests and biopsy of the tumor...
-
Product Insights
NewThymoma (Thymic Epithelial Tumor) – Drugs In Development, 2024
Empower your strategies with our Thymoma (Thymic Epithelial Tumor) – Drugs In Development, 2024 report and make more profitable business decisions. Thymoma, also known as thymic epithelial tumor, is a rare type of cancer that originates in the thymus gland, a small organ located behind the breastbone and in front of the heart. The thymus gland plays a role in the development of certain immune cells and is most active during childhood but gradually becomes less active with age. Thymomas are...
-
Product Insights
NewColorectal Tumor – Drugs In Development, 2024
Empower your strategies with our Colorectal Tumor – Drugs In Development, 2024 report and make more profitable business decisions. Colorectal cancer, or colon cancer, is a disease where cells in the colon or rectum grow out of control. Most colorectal cancers start as polyps, which are growths on the inner lining of the colon or rectum. Risk factors for colorectal cancer include increased age. Symptoms include change in bowel habits, rectal bleeding or blood in the stool, abdominal discomfort, weakness, and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ASP-3082 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ASP-3082 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ASP-3082 in Pancreatic Ductal Adenocarcinoma Drug Details: ASP-3082 is under development...
-
Product Insights
NewNet Present Value Model: Harpoon Therapeutics Inc’s HPN-536
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GM-2505 in Depression
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. GM-2505 in Depression Drug Details: GM-2505 is under development for the treatment of depression and...